With the long period of no concrete new information/data, it certainly could be worrisome. However, when I do a biotech stock screening at present, Anavex is still up there with the best risk/reward ratio as far as I can tell. So I would choose to invest again and have done a bit more at these prices.
With the long period of no concrete new information/data, it certainly could be worrisome. However, when I do a biotech stock screening at present, Anavex is still up there with the best risk/reward ratio as far as I can tell. So I would choose to invest again and have done a bit more at these prices.
With the long period of no concrete new information/data, it certainly could be worrisome. However, when I do a biotech stock screening at present, Anavex is still up there with the best risk/reward ratio as far as I can tell. So I would choose to invest again and have done a bit more at these prices.